Platinum International Health Care Fund
|Finding Value in the Much-Hyped AI Space|
|Biotechs Preparing for the Next Chapter of Growth|
|Biotech, Down but Absolutely Not Out|
|Platinum International Health Care Fund Update|
|One-on-One with Platinum's Dr Bianca Ogden|
About this Fund
|FUND MANAGER||Platinum Asset Management|
|ASSET CLASS||GLOBAL EQUITIES|
|INVESTMENT STYLE||The Fund primarily invests in health care companies listed on securities markets around the world.|
|INVESTMENT PROFILE||The Fund aims to provide capital growth over the long-term.|
|CURRENCY MANAGEMENT||Active management|
|BENCHMARK||MSCI All Country World Health Care Net Index in $A|
|FUND SIZE||MSCI All Country World Health Care Net Index in $A|
|NO. OF HOLDINGS||30-100|
|FEES||C class fee option: 1.37% p.a. of the NAV|
Benefits of investing in the Platinum International Health Care Fund
The Funds are not suited to Investors who:
About the Fund
The fund seeks to take advantage of the changes and developments occurring in the fields of health care and medicine, and offers investors exposure to companies engaged in the provision of a wide range of products and services within the global healthcare ecosystem, from multinational pharmaceuticals to biotechs engaged in early stage research, from medical equipment makers to specialists in diagnostic and laboratory technologies, from hospitals to healthcare software providers.
To provide capital growth over the long-term by investing in health care companies from around the world, ranging from those companies engaged in early exploratory research through to those providing health care services directly to consumers such as hospitals and health insurance providers.
The Platinum International Health Care Fund primarily invests in health care companies listed on securities markets around the world. The portfolio will ideally consist of 30 to 100 securities that Platinum believes to be undervalued by the market. Cash may be held when undervalued securities cannot be found. However, the portfolio typically has 50% or more net equity exposure. Platinum may short-sell securities that it considers overvalued.
Why invest with Platinum?
Platinum is one of Australia's leading investment managers in international equities.
Platinum has an independent style of investment management driven by a thematic stock picking approach. The composition of a Fund's assets is determined largely by the availability of companies regarded as undervalued by Platinum rather than by macro economic modelling (referred to as top down asset allocation) or by reference to global share index weightings (referred to as benchmarking).
Platinum's investment strategy is applied with the aim of achieving absolute returns for Investors. This is our central endeavour. It is complemented by monthly and quarterly communications to keep Investors abreast of our perspective and portfolio positioning.
The Funds can be used as standâ€alone investment options for international exposure or may be used to complement the investment styles of other managers.
How we invest your money
The Fund primarily invests in health care companies listed on securities markets around the world. However, the Fund may have some exposure to unlisted investments. It invests in companies engaged in many aspects of providing products and services to the health care industry such as biotechnology, pharmaceuticals, diagnostics, laboratory technologies, distribution, hospitals and nursing care, health insurance and the provision of information technology to such companies.
The Fund will, at times, invest in companies engaged in early stage research and the development of new drugs or treatments. The clinical trial process for such developments has a long gestation period, taking from a few years to many decades to complete. These companies face significant scientific, regulatory and, at times, legal risks with these programs where it is impossible to be certain of a successful outcome. Many of these programs fail, which can impact the volatility and returns of the investment and the Portfolio. The global health care industry is subject to regulatory and political influences that can also be unpredictable and economically adverse.
The construction of the Portfolio can ameliorate only some of the risks associated with investing in companies engaged in the complexities of research and development that span many years. Investors should anticipate periods of significant fluctuations and recognise that some of the investments made by the Fund might take many years to realise their potential (if at all).
The Portfolio will ideally consist of 30 to 100 securities that Platinum believes to be undervalued by the market. Cash may be held when undervalued securities cannot be found. Platinum may short sell securities that it considers overvalued. Refer further to Disclosure Principle 8: Short selling' on page 14 of the PDS.
The Portfolio will typically have 50% or more net equity exposure.
The Portfolio is constructed in accordance with Platinum's Investment Strategy' - refer to page 4 of the PDS.